FDA Zooms In on Tracking Food by Lot Codes – Join the Chat?
Published Date: 10/9/2026
Notice
Summary
The FDA is hosting a virtual meeting on November 6, 2026, to talk about how to better track food by its lot numbers, making food safer and easier to trace. This affects food businesses who must follow new rules to keep better records. People can share ideas and concerns until December 6, 2026, helping shape flexible solutions without extra costs or hassles.
Analyzed Economic Effects
8 provisions identified: 6 benefits, 2 costs, 0 mixed.
Faster Tracing Means Fewer Illnesses
Lot-level tracking lets FDA trace contaminated foods faster, narrow the scope of recalls, and remove affected products from the supply chain more quickly. The rule says this will result in fewer foodborne illnesses and deaths.
Enforcement Delayed Until July 20, 2028
Congress directed FDA not to enforce the Food Traceability Rule before July 20, 2028. The rule’s original compliance date had been January 20, 2026, but FDA intends to comply with the July 20, 2028 directive.
Lot-Level Tracking and Recordkeeping Required
For foods on FDA’s Food Traceability List, businesses that manufacture, process, pack, or hold those foods must assign unique Traceability Lot Codes (TLCs) and record Key Data Elements (KDEs) at Critical Tracking Events (CTEs). These requirements are part of the Food Traceability Rule to support lot-level tracking.
Stakeholder Support for TLC Flexibilities
Many commenters supported allowing a reasonable range of Traceability Lot Codes or using inferred TLCs when shipping foods from distribution to retail, provided there are guardrails like documented practices and validation. Some commenters warned that such flexibilities could broaden recalls and reduce product-specific traceability.
Proposed Flexibilities for Returns and Donations
Stakeholders broadly supported providing flexibilities for 'eaches' (individual items), returns, and reclamations, and requested clarity on the donated food exemption so food recovery and donation are not discouraged. These items are viewed as relatively small or separated from original cases.
Confusion Over Intracompany Shipment Rules
Some stakeholders reported continued confusion about which records are required for intracompany shipments and asked for clarification. They requested flexibility to track incoming and outgoing TLCs with internal movement records that would be available on request.
Support for Simplified Retail-Transformer Rules
There was broad support for a simplified, modified recordkeeping framework for shipments from retail kitchens to affiliated stores (retail transformer shipments). Stakeholders favor a less complex approach for these retail-to-affiliate movements.
Stakeholder Push for GS1 Data Standard Recognition
Stakeholders strongly supported FDA recognizing GS1 as an acceptable data standard for identifying shipments of Food Traceability List items. FDA also posted a Frequently Asked Questions (FAQ) on data standards related to the rule.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-20719, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases (NIAID) is holding a private meeting from December 7-9, 2026, to review the skills and work of its researchers. This closed meeting protects personal privacy and focuses on making sure the team is top-notch. If you want, you can send written comments before the meeting, but no public attendance is allowed.
Next: 2026-20723, Agency Information Collection Activities: Proposed Collection; Comment Request
SAMHSA is asking to extend its approval to collect info through surveys and interviews that help understand substance use and mental health issues better. This extension won’t change what’s collected or add any extra work for people involved. It helps SAMHSA keep up-to-date data for smarter decisions without costing extra time or money.